Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (NYSE: WAT) announced that the location value="LC/us"U.S. FDA has expanded its use of Waters' Empower Chromatography Data Software and added NuGenesis Laboratory Management Software to support pharmaceutical testing. This transition to a common data management platform across five labs will enhance data retrieval and compliance with legislative mandates. Both software solutions will improve operational efficiencies for the FDA, allowing better management of analytical data vital for public health and safety.
Waters Corporation (NYSE:WAT) will live webcast its Q4 2021 financial results conference call on February 1, 2022, at 8:00 a.m. ET. Investors can access the presentation via Waters’ investor relations website. A replay will be available until February 15, 2022, at midnight ET. Waters, a leader in specialty measurement, has over 7,400 employees globally and operates in 35 countries, emphasizing innovations in chromatography and mass spectrometry.
Waters Corporation (NYSE:WAT) has expanded its waters_connect informatics platform to support tandem quadrupole mass spectrometers with the new MS Quan application. This software enhances quantitative analysis by cutting data review time by up to 50% and facilitating compliance and data integrity. It streamlines the processing of large sample sets and enables accurate results in a secure manner. The MS Quan app is now globally available as an upgrade for select Waters' mass spectrometers, aiding laboratories in analyzing food and environmental samples effectively.
Waters Corporation (NYSE:WAT) will present at the J.P. Morgan Healthcare Conference on January 10, 2022, at 8:15 AM EST. Udit Batra, Ph.D., President and CEO, will address the investment community virtually. Interested investors can access the live webcast through Waters’ investor relations website, with a replay available for 30 days. Waters has led innovations in chromatography and mass spectrometry for over 60 years, operating in 35 countries and employing over 7,400 individuals worldwide.
Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., President and CEO, will present at the Evercore ISI 4th Annual HealthCONx Healthcare Conference on November 30, 2021, at 12:10 PM EST. Investors can access the live webcast on the company's investor relations website, with a replay available for 90 days. Founded over 60 years ago, Waters is a leader in specialty measurement, including chromatography and mass spectrometry, with operations in 35 countries and products available in over 100 countries.
Summary not available.
Waters Corporation (NYSE: WAT) reported third quarter 2021 sales of $659 million, an 11% increase from $594 million in Q3 2020. GAAP EPS rose to $2.60, up from $2.03 year-over-year. Non-GAAP EPS was $2.66, reflecting a 23% increase. Key growth drivers included a 16% rise in pharmaceutical sales and 9% in industrial markets. The company anticipates full-year 2021 sales growth of 15%-16% and non-GAAP EPS between $10.94 and $11.04. Waters also experienced strong recurring revenue growth of 11% in Q3, alongside a 10% increase in instrument sales.
Waters Corporation (NYSE: WAT) and Sartorius (DAX: SRT:GR) have announced a partnership to enhance biopharmaceutical process development. Their collaboration integrates the Waters BioAccord LC-MS System with Sartorius’ Ambr multi-parallel bioreactor systems, enabling faster access to critical quality data. This integration can reduce analysis time from several weeks to just two days, aiding scientists in clone selection and process optimization. The initiative aims to meet the growing demand for upstream analytical data in the rapidly expanding biopharmaceutical market, projected to grow at a ~10% CAGR until 2025.
Waters Corporation (NYSE:WAT) and the University of Delaware have announced a multi-year partnership aimed at enhancing analytical solutions for the biopharmaceutical industry. The collaboration will take place at Immerse Delaware, a new research lab located on the university's STAR campus, focusing on improving drug quality, yields, and manufacturing efficiency. Through this partnership, Waters and university researchers will work on projects leveraging LC-MS technologies to address significant challenges in bioprocessing, ultimately aiming to accelerate the delivery of high-quality medicines.
Waters Corporation (NYSE:WAT) will host a live webcast for its Q3 2021 financial results on November 2, 2021, at 8:00 a.m. eastern time. Investors can access the webcast via the Waters investor relations website. A replay will be available until November 16, 2021, at midnight eastern time. Waters has over 60 years of experience in chromatography and mass spectrometry, employing more than 7,400 staff across 35 countries. The company continues to lead in specialty measurement solutions for life, materials, and food sciences.